Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Boehringer’s Spiriva Captures 10% Share Of New Prescriptions

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer and Boehringer Ingelheim's chronic obstructive pulmonary disease therapy Spiriva (tiotropium) has a 10% share of new prescriptions.

You may also be interested in...



Pfizer Expects To File 12 "Major" NDAs By The End Of 2006

The company's strategy to weather upcoming patent expirations includes plan to file 20 NDAs over the five-year period ending 2006, U.S. Pharmaceuticals President Pat Kelly tells investors.

Pfizer Expects To File 12 "Major" NDAs By The End Of 2006

The company's strategy to weather upcoming patent expirations includes plan to file 20 NDAs over the five-year period ending 2006, U.S. Pharmaceuticals President Pat Kelly tells investors.

Spiriva Off To “Great Start,” But Caduet Will Take Time

The launch of Caduet is moving more slowly than Pfizer had hoped, the company acknowledged during its second quarter conference call July 21

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel